ArticleFrontiers in oncology2023

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170).

Ga-Young Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.